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Abstract
Background: While quantification of viral loads has been successfully employed in clinical medicine and has provided
valuable insights and useful markers for several viral diseases, the potential of measuring bacterial DNA load to predict
outcome or monitor therapeutic responses remains largely unexplored. We tested this possibility by investigating bacterial
loads in Acinetobacter baumannii bacteremia, a rapidly increasing nosocomial infection characterized by high mortality,
drug resistance, multiple and complicated risk factors, all of which urged the need of good markers to evaluate
therapeutics.
Methods and Findings: We established a quantitative real-time PCR assay based on an A. baumannii-specific gene, Oxa-51,
and conducted a prospective study to examine A. baumannii loads in 318 sequential blood samples from 51 adults patients
(17 survivors, 34 nonsurvivors) with culture-proven A. baumannii bacteremia in the intensive care units. Oxa-51 DNA loads
were significantly higher in the nonsurvivors than survivors on day 1, 2 and 3 (P=0.03, 0.001 and 0.006, respectively).
Compared with survivors, nonsurvivors had higher maximum Oxa-51 DNA load and a trend of increase from day 0 to day 3
(P,0.001), which together with Pitt bacteremia score were independent predictors for mortality by multivariate analysis
(P=0.014 and 0.016, for maximum Oxa-51 DNA and change of Oxa-51 DNA, respectively). Kaplan-Meier analysis revealed
significantly different survival curves in patients with different maximum Oxa-51 DNA and change of Oxa-51 DNA from day 0
to day 3.
Conclusions: High Oxa-51 DNA load and its initial increase could predict mortality. Moreover, monitoring Oxa-51 DNA load
in blood may provide direct parameters for evaluating new regimens against A. baumannii in future clinical studies.
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Introduction
The successful employment of quantitative PCR to measure
viral load in clinical medicine has not only advanced our
understanding of pathogenesis of many viral diseases but also
provided useful markers for predicting outcome and/or monitor-
ing therapeutic responses [1]. The possibility of measuring
bacterial DNA load to predict outcome or evaluate therapeutics
in bacterial diseases, especially those with high mortality,
antimicrobial resistance, multiple and complicated risk factors,
has been raised but never been fully explored [1,2].
Acinetobacter baumannii (A. baumannii), a nonfermenting Gram-
negative aerobic coccobacillus which can survive for prolonged
periods in various environmental conditions, is an increasingly
important nosocomial pathogen [3]. Among the A. calcoaceticus- A.
baumannii complex, which included genospecies 1, 2, 3 and 13TU,
A. baumannii (genospecies 2) is primarily associated with human
diseases [4]. Nosocomial infection caused by A. baumannii has
increased substantially, especially among patients in the ICU [3–6]
or immunocompromized hosts [3,4,6]. It is a life-threatening
opportunistic infection among critical ill patient [7,8]. Patients
with A. baumannii infection have been reported to be associated
with higher mortality and longer hospital stay compared with
other infections [3,7,8]. In addition to pneumonia, bacteremia is
the most common focus of A. baumannii infection [4]. Due to rapid
increase in the drug resistance of A. baumannii, the choices of
antimicrobial agents were limited [3,4,9]. Previous studies have
identified multiple and complicated risk factors for the high
mortality of A. baumannii bacteremia [5,6,10–15], but none has
investigated the roles of bacterial load in the disease outcome.
The relationship between the magnitude of bacteremia and
clinical outcome was originally demonstrated by semiquantitative
blood culture [16,17]. The drastic decrease in the sensitivity of
blood culture after antimicrobial treatment and the time required
for blood culture limited the application of this approach [2,18].
Recently, several studies using quantitative PCR assays have
shown high initial bacterial DNA loads in blood correlated with
disease severity and mortality in infection caused by Streptococcus
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14133pneumoniae, Neisseria meningitides, and methicillin-resistant Staphylo-
coccus aureus (MRSA) [19–22]. However, the change in bacterial
DNA load during the course of infection and its relationship to
disease outcome or therapy remain largely unclear. We reported
previously that high levels of mecA DNA in blood after 3 and 7 days
of antibiotic therapy were associated with mortality in MRSA
bacteremia [21], suggesting sequential bacterial DNA load in
blood can be used to evaluate therapeutic responses. In this study,
we established a quantitative real-time PCR assay by using an A.
baumannii-specific gene, Oxa-51, to measure both the initial and
sequential A. baumannii loads in blood from patients with A.
baumannii bacteremia and to investigate the relationships to disease
outcome [23].
Methods
Patients and blood samples
This prospective observational study was conducted in accor-
dance with the principles expressed in the Declaration of Helsinki
at the National Taiwan University Hospital, a medical center with
a 2,200-bed capacity in Taiwan. With the approval of the
Institutional Review Board (No. 200809045R), adult patients
admitted to the medical or surgical ICU between 1 April 2008
and 28 February 2009 were enrolled once a positive blood culture
for A. baumannii was reported. Blood cultures were taken when
clinical symptoms/signs of infection such as fever, shock, etc. were
observed. The Board waived the need for informed consent, since
this study required no additional blood drawing from the study
patients in ICU and all the data were analyzed anonymously (Text
S1 and S2). All blood cultures were performed by the Bactec 9240
system (Becton Dickson, Sparks, MD) in the microbiological
laboratory. A. baumannii complex was identified by classic methods
and verified by the Phoenix system (BD Diagnostics, Sparks, MD)
[24], followed by a disk diffusion susceptibility test with
gentamicin, amikacin, ciprofloxacin, levofloxacin, cefepime, cef-
tazidime, aztreonam, ticarcillin/clavulanate, meropenem, and
ampicillin/sulbactam [25]. The susceptibility of tigecycline was
determined by the agar dilution method, in which MIC # 2 mg/
mL was considered the break point [26], and that of colistin by E-
test [25,27]. Genospecies A. baumannii was defined by A. baumannii
complex positive for the Oxa-51 by real-time PCR assay [23]. The
course of A. baumannii bacteremia in each patient was carefully
monitored by clinical parameters and routine laboratory tests.
Whole blood samples in EDTA-containing tubes taken before and
on the day of reporting A. baumannii bacteremia were retrospec-
tively obtained from the central laboratory. After that, blood
samples were collected daily for the first week and two to three
times a week thereafter.
Clinical data and definitions
The demographic, clinical, laboratory and culture data for each
patient were collected (Tables 1 and 2). The underlying illness was
assessed by the Charlson score [28], and clinical severity by the
acute physiology and chronic health evaluation II (APACHE II),
Pitt bacteremia scores [29], and sequential organ failure assess-
ment score (SOFA) score [30].
Day 0 was the day on which the first blood sample positive for A.
baumannii by culture was drawn, and the days after that were
designated consecutively. Since the average time of reporting A.
baumannii bacteremia was 72 h in our study, the period of empirical
therapy was defined as from day 0 to day 3. Extensively resistant A.
baumannii (ERAB) was defined as A. baumannii resistant to the
commonly used anti-pseudomonas antibiotics (cephalosporins,
extended-spectrum penicillins, carbapenems, aminoglycosides,
fluoroquinolones) and ampicillin/sulbactam determined by disc
diffusion method [15,25]. Appropriate empirical therapy was
defined if A. baumannii was susceptible in vitro to at least one
antibiotic used within 48 hours from day 0. Aminoglycoside
monotherapy without combination of other susceptible antibiotics
was considered as inappropriate [9]. For ERAB, the possibly
appropriate antibiotics included tigecycline and colistin. Although
the MIC breakpoint for tigecycline susceptibility was 2 mg/mL
according to the FDA definition for Enterobacteriaceae [26], it was
considered as inappropriate therapy if used alone for A. baumannii
blood stream infection with MIC §1 mg/mL [9]. The overall and
initial changes of Oxa-51 DNA load were assessed by the summary
statistics for each patient, in which the slopes of linear regression of
log Oxa-51 DNA copies/mL over the whole course and from day 0
to day 3, respectively, were calculated. Co-infection was defined by
thepresence of pathogensotherthan A. baumannii inblood culture at
the same time when the first blood sample positive for A. baumannii
by culture was drawn. Subsequent blood stream infection was
defined by the presence of pathogens other than A. baumannii in
blood culture within 14 days after the onset of A. baumannii
bacteremia.
Patients, who fulfilled the definition of A. baumannii bacteremia
related death including (1) blood culture positive for A. baumannii at
the time of death, (2) death before resolution of symptoms and
signs, and (3) death within 14 days after the onset of A. baumannii
bacteremia without another explanation, were classified as the
nonsurvivor group. Patients who survived the episode were
classified as the survivor group.
DNA extraction
One milliliter of whole blood from patients or A. baumannii-
spiked whole blood was treated with 3 mL of red blood cell lysis
solution (Gentra Systems, Minneapolis, MN) at room temperature
for 5 min, followed by centrifugation at 5,0006 g for 10 min to
obtain the pellets, which were resuspended in enzyme solution
(20 mM Tris [pH 8.0], 2 mM EDTA, 1.2% Triton, lysozyme
20 mg/mL) and subjected to DNA extraction using QIAamp
DNA minikit (Qiagen, Hilden, Germany) [21]. The final eluate
(100 ml) was stored at –20uC until use. Whole blood samples from
healthy donors served as negative controls. DNA extraction and
PCR were carried out in separate rooms, and precautions were
taken to prevent contamination [31].
Quantitative real-time PCR
The Oxa-51-specific primers (F Oxa-51 and R Oxa-51) and
probe (P Oxa-51) were designed based on the Oxa-51 sequence in
GenBank and Primer Express software v2.0. Plasmid Oxa-51/
pCRII-TOPO, which contained a 431-bp fragment of the Oxa-51
gene in pCRII-TOPO, was used as the standard and its copy
number was calculated based on the concentration determined by
spectrophotometry and molecular weight [21,32] (Text S3). The
sequences of F Oxa-51, R Oxa-51 and P Oxa-51 are 59-
TTTAGCTCGTCGTATTGGACTTGA-39,5 9-CGGAGAAC-
GACTCCTCAT TAAAAA-39 and 59-TGGCAATGCAGATA
TCGGTACCCAAGTC-39, respectively. An aliquot of extracted
DNA and known copy numbers of Oxa-51 DNA standards were
subjected to real-time PCR. Briefly, a 25 ml reaction mixture
containing 12.5 ml of 2x TaqMan universal PCR master mix,
2.5 ml of 10 pmol/ml of each of F Oxa-51, R Oxa-51 and P Oxa-
51, Oxa-51 DNA standards or extracted DNA, and nuclease free-
water was subjected to real-time PCR with an ABI Prism 7000/
7500 sequence detector (Applied Biosystems, Foster City, CA).
The amplification conditions were 50uC for 2 min and 95uC for
10 min, followed by 50 cycles of 95uC for 15 s and 60uC for
A. baumannii Bacteremia
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by the cycle number required to reach the threshold, which was 10
times the standard deviation of the mean baseline emission
calculated for cycles 3 to 15 [21]. Since 5 ml of the 100 ml DNA
eluate, which was derived from 1 mL of whole blood samples, was
used in each reaction mixture, the Oxa-51 DNA copy number per
reaction was multiplied by 20 to determine the copy numbers of
Oxa-51 DNA per mL whole blood. The sensitivity of the assay was
20 copies per mL.
Statistical analysis
Mann-Whitney U test and Fisher’s exact test were used to
compare continuous variables and categorical variables, respec-
tively, between two groups. Log-rank test and Kaplan-Meier
survival curve were used for survival analysis, and the results were
verified by multivariate Cox’s proportional hazard model.
Multivariate logistic regression analysis including all variables
such as age, sex, underlying diseases, laboratory data, infection
foci, invasive procedure (central catheter, ventilator), appropriate
empirical antibiotics and bacterial load was conducted to identify
predictors for mortality (Text S4). Data was analyzed using Stata
software, version 10 (StataCorp, College Station, Texas).
Results
Quantitative real-time PCR assay for Oxa-51 gene
We first established a standard curve by using increasing copy
numbers (5 to 5610
8 copies) of the plasmid Oxa-51/pCRII-
TOPO in the assay (r=0.9992, Text S3). We next tested DNA
extracted from increasing CFUs (9610
1 to 9610
6 CFUs) of a
previously reported A. baumannii isolate 2003I053 [32], which had
been spiked with whole blood from a healthy volunteer, and found
a linear curve between the CFUs and Oxa-51 copy numbers
(r=0.9942), demonstrating the accuracy of this assay for
quantifying A. baumannii in whole blood (Text S3). Moreover, the
Oxa-51 copy numbers of DNA extracted from A. baumannii-spiked
whole blood that had been stored at 4uC for up to 4 days remained
stable, suggesting the feasibility of this assay to quantify A.
baumannii in stored whole blood samples (Text S3).
Table 1. Clinical and laboratory characteristics of study patients with A. baumannii bacteremia.
Characteristics
a Total (n=51)
Nonsurvivor group
(n=34)
Survivor group
(n=17) P
Age 61.5 (48.9–74.2) 59.9 (48.0–74.6) 61.5 (49.0–71.7) 0.84
Sex, M/F 33/18 22/12 11/6 1.00
Days of prior hospitalization
b 18 (10–41) 19.5 (10–47.3) 18 (10–29.5) 0.75
Days of prior ICU stay
b 10 (0–18) 10 (0.8–16.3) 14 (0–18) 0.80
APACHE II score, ICU admission 26 (20.5–36) 27 (20.5–36) 25.5 (20.3–35) 0.73
Underlying illness
Charlson score 3 (2–6) 3 (2–6) 4 (2–6) 0.91
Diabetes mellitus 20 (39.2) 11 (32.4) 9 (52.9) 0.23
Congestive heart failure 7 (13.7) 5 (14.7) 2 (11.8) 1.00
Chronic renal insufficiency 16 (31.4) 11 (32.4) 5 (29.4) 1.00
Immunosuppressants
c 22 (43.1) 18 (52.9) 4 (23.5) 0.07
Leukemia 7 (13.7) 7 (20.6) 0 (0) 0.08
Lymphoma 3 (5.9) 2 (5.9) 1 (5.9) 1.00
Focus of infection
Primary bacteremia 11 (21.6) 7 (20.6) 4 (23.5) 1.00
Pneumonia 33 (64.7) 24 (70.6) 9 (52.9) 0.23
Intra-abdominal infection 4 (7.8) 2 (5.9) 2 (11.8) 0.59
Surgical site infection 4 (7.8) 4 (11.8) 0 (0) 0.29
Laboratory data on day 0
b
White blood cell count (1000/mL) 10.29 (2.42–20.34) 8.36 (0.55–20.64) 12.07 (8.50–19.97) 0.19
Hemoglobin (g/dL) 9.4 (8.5–10.4) 9.2 (8.2–10.5) 9.6 (8.9–10.7) 0.35
Platelet count (1000/mL) 73 (41–134) 56 (19–96.8) 134 (74–275.5) ,0.001
AST
d (U/L) 50 (25–95) 67 (30–117) 35 (17.5–58.3) 0.15
Total bilirubin (mg/dL) 2.56 (0.83–9.06) 3 (0.8–25.5) 1.9 (0.7–3.3) 0.32
Creatinine (mg/dL) 1.8 (1.1–3.2) 1.9 (1.1–3.8) 1.7 (1.1–3) 0.81
C-reactive protein (mg/dL) 9.6 (4.6–16.4) 9.8 (5.3–21.1) 8.7 (2.3–12.7) 0.37
aData are median (interquartile range) for continuous variables and number of cases (percentage) for categorical variables, with two-tailed Mann-Whitney U test for the
former and Fisher’s exact test for the later.
bDays of hospitalization and ICU stay prior to day 0, which was the day on which the first blood sample positive for A. baumannii by culture was drawn.
cImmunosuppressants included antineoplastic therapy within 6 weeks of the onset of A. baumannii bacteremia, corticosteroids at a dose § 20 mg of prednisolone daily
for at least 2 weeks or 30 mg of prednisolone daily for at least 1 week before a positive blood culture for A. baumannii, and other immunosuppressants such as
cyclophosphamide [15].
dAST: aspartate aminotransferase.
doi:10.1371/journal.pone.0014133.t001
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by examining DNA extracted from 85 isolates including common
nosocomial pathogens such as E. coli, K. pneumoniae, E. cloacae, P.
aeruginosa, S. maltophilia, E. faecium and MRSA, as well as
Acinetobacter genospecies 3, 13TU and 2 (A. baumannii) in the
assay [32–35], which detected positive signal only in the DNA
extracted from A. baumannii but not in those from other isolates.
Study Patients
Table 1 summarizes the clinical and laboratory characteristics
of the 51 patients with A. baumannii bacteremia, including 34
nonsurvivors and 17 survivors. They were predominantly males
with a median age of 61.5 years, and were all critically ill with high
APACHE II score (median: 26). There was no difference between
the two groups in the APACHE II or Charlson score, the number
of days of hospitalization and of ICU stay prior to A. baumannii
bacteremia, individual underlying disease such as leukemia or
lymphoma, immunosuppressant, foci of infection, or initial
laboratory data except lower platelet counts in the nonsurvivors.
Compared with the survivors, the nonsurvivors had higher Pitt
bacteremia score and SOFA score on day 0, and higher frequency
of ERAB and resistance to ampicillin/sulbactam (P=0.02 and
P,0.001, Mann-Whitney U test, two tailed; P=0.04 and 0.01,
Fisher’s exact test, respectively) (Table 2). There was no difference
in the co-infection, subsequent blood stream infection, antimicro-
bial resistance to other groups of antibiotics, antibiotics used
Table 2. Antimicrobial susceptibility and usage, bacteremia score and Oxa-51 DNA level of study patients with A. baumannii
bacteremia.
Characteristics
a Total (n=51)
Nonsurvivor
group (n=34)
Survivor group
(n=17) P
Multivariate
f odds
ratio [95% CI] P
Pitt bacteremia score, on day 0
b 5 (3–7) 5.5 (4–7.3) 4 (2–6) 0.02 1.55 [0.94–2.57] 0.087
SOFA score
c 14.5 (11–19) 16 (13.5–19) 10.5 (6–13) ,0.001
Co-infection 16 (31.4) 10 (29.4) 6 (35.3) 0.75
Subsequent blood stream infection 2 (3.9) 1 (2.9) 1 (5.9) 1.00
Antimicrobial resistance to
Anti-pseudomonas Penicillin 43 (89.6) 29 (87.9) 14 (93.3) 1.00
Anti-pseudomonas Cephalosporin 45 (88.2) 31 (91.2) 14 (82.4) 0.39
Carbapenem 38 (74.5) 25 (73.5) 13 (76.5) 1.00
Aminoglycosides 44 (86.3) 31 (91.2) 13 (76.5) 0.20
Fluoroquinolones 48 (94.1) 32 (94.1) 16 (94.1) 1.00
Ampicillin/Sulbactam 31 (60.8) 25 (73.5) 6 (35.3) 0.01
Tigecycline 10 (20.8) 8 (24.2) 2 (13.3) 0.47
Colistin 0 (0) 0 (0) 0 (0)
ERAB
d 27 (52.9) 22 (64.7) 5 (29.4) 0.04 1.99 [0.21–18.71]
h 0.55
Antibiotics used in empirical therapy
Anti-pseudomonas Penicillin 6 (11.8) 2 (5.9) 4 (23.5) 0.09
Anti-pseudomonas Cephalosporin 16 (31.4) 10 (29.4) 6 (35.3) 0.75
Carbapenem 26 (51.0) 21 (61.8) 5 (29.4) 0.04
Fluoroquinolones 12 (23.5) 8 (23.5) 4 (23.5) 1.00
Ampicillin/Sulbactam 8 (16.7) 5 (14.7) 3 (17.7) 1.00
Tigecycline 5 (9.8) 4 (11.8) 1 (5.9) 0.65
Colistin 5 (9.8) 4 (11.8) 1 (5.9) 0.65
Appropriate empirical therapy
e 17 (33.3) 12 (35.3) 5 (29.4) 0.76
Day 3 Oxa-51 DNA (log/copies/mL)
b 1.00 (0–3.01) 2.81 (0.59–3.48) 0 (0–1.69) 0.006 2.19 [1.18–4.07]
g 0.013
g
Maximum Oxa-51 DNA (log copies/mL),
day 0 – day 3
b
3.04 (2.30–3.62) 3.38 (2.70–4.07) 2.30 (1.71–2.89) ,0.001 10.25 [1.61–65.46] 0.014
Change of Oxa-51 DNA, day 0
b – day 3
(D log copies/mL/day)
0.12 (20.73–0.76) 0.40 (20.09–0.97) 20.77 (21.25– 20.14) ,0.001 3.17 [1.24–8.12] 0.016
aData are median (interquartile range) for continuous variables and number of cases (percentage) for categorical variables, with two-tailed Mann-Whitney U test for the
former and Fisher’s exact test for the later.
bDay 0 was the day on which the first blood sample positive for A. baumannii by culture was drawn.
cSOFA: Sequential organ failure assessment. Not included in the final multivariate regression model due to small case numbers (Text S4).
dERAB: Extensively resistant A. baumannii.
eAppropriate empirical therapy is defined when A.baumannii is susceptible to at least one antibiotic used within 48 hours of day 0 except aminoglycoside monotherapy
(see Methods).
fMultivariate logistic regression model: n=40, adjusted generalized R
2=0.634, estimated area under the ROC curve =0.92. Deviance goodness-of-fit (GOF) test
P=0.87.0.05 (df =36); Pearson GOF test P=0.88.0.05 (df =36); Hosmer and Lemeshow GOF test P=0.98.0.05 (df =8).
gDiscard ‘‘Maximum Oxa-51 DNA’’ and ‘‘Change of Oxa-51 DNA’’, both of which require daily monitoring of Oxa-51 DNA in blood.
hERAB was considered in the predicting model of mortality based on the three independent predictors, Pitt bacteremia score, maximum Oxa-51 DNA and change of
Oxa-51 DNA from day 0 to day 3.
doi:10.1371/journal.pone.0014133.t002
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empirical therapy between the two groups (Table 2 and Table S1).
Higher levels of Oxa-51 DNA in nonsurvivors than
survivors
We then employed the real-time PCR assay to quantify Oxa-51
DNA in 318 sequential blood samples from 51 patients. We first
examined sequential Oxa-51 DNA loads over time in 4 patients,
including 2 nonsurvivors and 2 survivors. As shown in Figure 1, a
decreasing trend of the Oxa-51 DNA level was found in the
survivors, whereas continuously high levels of Oxa-51 DNA were
found in the nonsurvivors. To investigate the overall change of
Oxa-51 DNA load during the course of infection, we analyzed the
slope of Oxa-51 DNA load. While all survivors had a decline in
Oxa-51 DNA over time, more than half of the nonsurvivors
showed an upward slope at death (P=0.01, Mann-Whitney U test,
two tailed) (Figure 1E).
We next focused on initial Oxa-51 DNA loads from day 0 to day
3, which corresponded to the period of empirical therapy. The
levels of Oxa-51 DNA were significantly higher in the non-
survivors than survivors on day 1, day 2 and day 3 (P=0.03, 0.001
and 0.006, respectively, Mann-Whitney U test, two tailed)
(Figure 2), so was the maximum Oxa-51 DNA between day 0
and day 3 (Table 2) [20]. We then examined the change of Oxa-51
DNA load from day 0 to day 3. As shown in Figure 3A, a trend of
increase was found in the majority of nonsurvivors, whereas a
Figure 1. Sequential Oxa-51 DNA loads in blood during the course of A. baumannii bacteremia. Sequential whole blood samples from 2
nonsurvivors (A, B) and 2 survivors (C, D) with A. baumannii bacteremia were subjected to DNA extraction and the Oxa-51 real-time PCR assay. The
lines beneath indicate inappropriate (—) and appropriate (—) antibiotic therapy, and the asters indicate death. (E) Overall change of Oxa-51 DNA load
in blood for patients with A. baumannii bacteremia (27 nonsurvivors, 13 survivors) assessed by the slope of the linear regression of log Oxa-51 DNA
copies per mL plotted against time.
doi:10.1371/journal.pone.0014133.g001
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copies/mL/day, P,0.001, Mann-Whitney U test, two tailed). To
further investigate whether appropriate empirical antibiotics affect
the Oxa-51 DNA change during this period, we analyzed
subgroups of patients. Among those receiving inappropriate
empirical antibiotics, nearly all nonsurvivors showed increasing
Oxa-51 DNA compared with survivors (P,0.001, Mann-Whitney
U test, two tailed) (Figure 3B). Among those receiving appropriate
empirical antibiotics, there was no difference in the initial Oxa-51
DNA change between the two groups (Figure 3C). Interestingly,
the nonsurvivors receiving appropriate empirical antibiotics
showed a trend of no or less increase in Oxa-51 DNA compared
with those receiving inappropriate empirical antibiotics (P,0.001,
Mann-Whitney U test, two tailed) (left panels, Figures 3B and 3C).
Predictors for mortality
Multivariatelogisticregressionanalysisincludingallthe variables
in Tables 1 and 2 revealed that Pitt bacteremia score, maximum
Oxa-51 DNA and change of Oxa-51 DNA from day 0 to day 3 were
three independent predictors for mortality (Table 2). Excluding
‘‘maximum Oxa-51 DNA’’ and ‘‘change of Oxa-51 DNA’’, which
required daily monitoring, the single day measurement, Oxa-51 on
day 3, was the most potent independent predictor for those who
survived more than 3 days (odds ratio [OR], 2.19; 95% confidence
interval [CI], 1.18–4.07; P=0.013). The goodness-of-fit (GOF) test
suggested a good fit of the multivariate logistic regression model to
binary data and thus a strong prediction (Text S4). Moreover, the
predicting model based on the three independent predictors had a
positivepredictivevalue of89.3%and a negative predictivevalueof
83.3% with the estimated area under receiver operating charac-
teristic (ROC) curve of 0.9202, which was higher than that of
0.6581 based on Pitt bactermia score alone.
Kaplan-Meier survival analysis
Based on the maximum Oxa-51 DNA from day 0 to day 3, three
groups of patients had different survival curves. All patients with
high maximum Oxa-51 DNA (.4 log copies/mL) during empirical
therapy died within 17 days, whereas 70% of patients with low
maximum Oxa-51 DNA (,2 log copies/mL) survived (P=0.003,
log-rank test) (Figure 4A). Moreover, based on the increase or
decrease in Oxa-51 DNA from day 0 to day 3, two groups of
patients had different survival curves (P,0.001, log-rank test)
(Figure 4B). These were further supported by multivariate Cox’s
proportional hazard analysis (Table 3). Similarly, the survival
curves based on a single day measurement of Oxa-51 DNA on day
2o rd a y3( .3o r,3 log copies/mL) were significantly different
(data not shown).
Discussion
In light of the rapid increase in the antimicrobial resistance of A.
baumannii, limited choice of antimicrobial agents and multiple
complicated risk factors associated with its high mortality, it is
important to identify good parameters for evaluating therapeutic
responses to new or combination regimens in well controlled
clinical studies [3,4,9]. In this study, we established an Oxa-51
quantitative real-time PCR assay to measure A. baumannii loads in
blood from patients with A. baumannii bacteremia. Compared with
the survivors, the nonsurvivors had higher maximum Oxa-51 DNA
load and an increased trend from day 0 to day 3; both parameters
and the single day measurement of Oxa-51 DNA on day 3, the day
when blood culture reports were available from most clinical
laboratories, were independent predictors for mortality by multi-
variate analysis (Table 2). To our knowledge, this is the first report
demonstrating high A. baumannii loads in blood were associated with
mortality. Moreover, nonsurvivors receiving appropriate antibiotics
showed a trend of less increase in Oxa-51 DNA during the empirical
period compared with those receiving inappropriate antibiotics,
suggesting that monitoring Oxa-51 DNA load in blood could
provide simple and direct parameters for evaluating therapeutic
response of A. baumannii bacteremia in future clinical trials.
Several risk factors for mortality of A. baumannii bacteremia have
been identified by different studies, such as septic shock [11,14],
high Pitt bacteremia score [15], immunosuppressant [11,15], age,
recent surgery, acute respiratory failure, acute renal failure [11],
Figure 2. Initial Oxa-51 DNA load from day 0 to day 3 in patients with A. baumannii bacteremia (34 nonsurvivors, 17 survivors). Data
are presented as median (line), interquartile range (box) and range.
doi:10.1371/journal.pone.0014133.g002
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doi:10.1371/journal.pone.0014133.g003
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coagulation, and inappropriate antibiotics usage [5]. With one
exception [5], the majority of these were retrospective studies,
which might be potentially biased by retrospective recall. We
carried out a prospective study and included all factors studied in
the multivariate logistic regression analysis, and three independent
factors, maximum Oxa-51 DNA, its change from day 0 to day 3
and Pitt bacteremia score were identified (Table 2). These findings
suggest both bacterial and host factors are important. The possible
role of appropriate empirical antibiotic therapy was suggested by
the trend of less increase in Oxa-51 DNA in the subgroup of
nonsurvivors who received appropriate antibiotics compared with
those receiving inappropriate antibiotics (Figures 3B and 3C).
Analysis of this subgroup and the survivors receiving appropriate
empirical antibiotics, of which both had an indistinguishable trend
of Oxa-51 DNA change (Figure 3C), revealed that SOFA score and
platelet counts were different (P=0.06 and 0.03, respectively,
Mann-Whitney U test, two tailed), suggesting host factors play a
key role in determining mortality in this subgroup. The
importance of host factors was further suggested by comparing
the left panels of Figures 3B and 3C, in which appropriate
empirical antibiotics were strongly associated with decreasing Oxa-
51 DNA load (P,0.001, Mann-Whitney U test, two tailed),
however, all patients in both groups died. This might be due to
host factors; most of our patients had high APACHE II score
(interquartile range [IQR], 20.5–36), Charlson score (IQR, 2–6)
Figure 4. Kaplan-Meier survival curves in patients with A. baumannii bacteremia. Comparison among subgroups with different maximum
Oxa-51 DNA load (A) and increased or decreased Oxa-51 DNA (B) from day 0 to day 3.
doi:10.1371/journal.pone.0014133.g004
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bacterial factor, antimicrobial resistance, was also carefully
examined. Although ERAB was significantly associated with
mortality in the univariate analysis, it was not significant in the
multivariate analysis (OR, 1.99; 95% CI, 0.21–18.71; P=0.55)
(Table 2). Similarly, sulbactam resistance was not significantly
associated with mortality in the multivariate analysis (Table 2).
Although SOFA score was strongly associated with mortality in
the univariate analysis (Table 2), it was not included in the
multivariate analysis due to small case number with SOFA score
on day 0 available in our prospective observational study design.
Nonetheless, including SOFA score in the multivariate logistic
regression analysis revealed a similar final model, which included
SOFA (OR, 1.65; 95% CI, 1.02–2.66; P=0.04), change of Oxa-51
DNA, day 0 – day 3 (OR, 6.93; 95% CI, 1.00–48.15; P=0.05)
and maximum Oxa-51 DNA, day 0 – day 3 (OR, 14.93; 95% CI,
0.65–341.06; P=0.09). The sensitivity, specificity, positive predic-
tive value and negative predictive value were 100%, 87.5%,
95.2%, and 100%, respectively. The area under ROC curve was
0.9688. In multivariate Cox’s proportional hazard model analysis,
SOFA (Hazard ratio [HR], 1.17; 95% CI, 1.03–1.32; P=0.01)
and change of Oxa-51 DNA, day 0 – day 3 (HR, 1.63; 95% CI,
1.08–2.49; P=0.02) were independent factors for mortality.
Of the 43 follow-up blood cultures from the 51 patients, only 3
(6.98%) were positive and 40 were negative, of which 12 had
detectable Oxa-51 DNA (median 2.0 log/copies/mL, interquartitle
range 1.6 to 2.6 log/copies/mL). This could be due to a drastic
decrease in the sensitivity of blood culture after antibiotic usage as
reported previously [2,18]. Alternatively, the possibility that the
Oxa-51 DNA detected in these samples was derived from dead or
degraded bacteria rather than viable bacteria can not be
completely ruled out. A recent study examining the amounts of
Neisseria meningitidis in blood by quantitative PCR and simultaneous
culture reported that the DNA copy numbers were more than 2
logs higher than CFU numbers, suggesting significant amounts of
non-viable bacteria were present in vivo [22]. Nonetheless, the
good correlation between bacterial DNA load and disease severity
and/or outcome demonstrated in different bacterial infections,
including Streptococcus pneumoniae, Neisseria meningitides, MRSA and A.
baumanii in this study, strongly suggested bacterial DNA load,
though derived from both viable and dead bacteria, could be a
useful marker to predict disease outcome [19–22].
There are several limitations of this study. First, the sample size
was small. Future study with a larger sample size is needed to
verify our observations and the applicability of this method in
clinical practice. Second, this study enrolled only critically ill
patients in ICU. Future study enrolling patients from general
wards is also needed to investigate the roles of Oxa-51 DNA load in
non-critically ill patients. Moreover, the relationship of the kinetics
of Oxa-51 DNA load in blood to antibiotic regimens and other
factors during the course of infection require further investigation.
Nonetheless, our findings that high and increased Oxa-51 DNA
load can predict mortality in A. baumannii bacteremia support the
notion that measuring bacterial DNA load could predict disease
outcome or monitor therapeutic responses, and may have
implications to our understanding of pathogenesis, particularly
for those bacterial diseases with high mortality, multiple and
complicated risk factors.
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